Difference between revisions of "Team:Duke/Integrated Practices"
(Prototype team page) |
|||
| Line 14: | Line 14: | ||
<div class="column full_size"> | <div class="column full_size"> | ||
| + | <h1>Societal Impact </h1> | ||
| + | <p>The optimized biosynthesis of Taxol has the potential for drastically decreasing the price of Taxol production, and ostensibly, decreasing the price of anticancer treatments using Taxol. We conducted a social policy analysis which looked at the current anticancer drug market and limitations to cancer treatments to look at who will benefit most from the decrease of Taxol treatment. Unfortunately, the current anticancer drug market incentivizes high prices regardless of research, development and production costs. This peculiarity is compounded with issues in accessibility which continue to impact low-income individuals and will not be resolved with a decrease in the price of Taxol. The results of our analysis indicate that for the biosynthesis of Taxol as well as similar price decreases in other pharmaceuticals, scientists and policymakers alike will have to address more systemic issues in the healthcare system in order for price decreases to truly impact a broad range of individuals. </p> | ||
| + | |||
| + | <!-- | ||
<p>Do you want to be considered for the <a href="https://2016.igem.org/Judging/Awards#SpecialPrizes">Best Integrated Human Practices award</a>? Help the judges consider your team for this award by describing your work on this page.</p> | <p>Do you want to be considered for the <a href="https://2016.igem.org/Judging/Awards#SpecialPrizes">Best Integrated Human Practices award</a>? Help the judges consider your team for this award by describing your work on this page.</p> | ||
| Line 23: | Line 27: | ||
<li><a href="https://2015.igem.org/Team:Edinburgh/Practices">Edinburgh 2015</a></li> | <li><a href="https://2015.igem.org/Team:Edinburgh/Practices">Edinburgh 2015</a></li> | ||
</ul> | </ul> | ||
| − | + | --> | |
</div> | </div> | ||
Revision as of 02:49, 19 October 2016
★ ALERT!
This page is used by the judges to evaluate your team for the Best Integrated Human Practices award.
Delete this box in order to be evaluated for this medal. See more information at Instructions for Pages for awards.
Societal Impact
The optimized biosynthesis of Taxol has the potential for drastically decreasing the price of Taxol production, and ostensibly, decreasing the price of anticancer treatments using Taxol. We conducted a social policy analysis which looked at the current anticancer drug market and limitations to cancer treatments to look at who will benefit most from the decrease of Taxol treatment. Unfortunately, the current anticancer drug market incentivizes high prices regardless of research, development and production costs. This peculiarity is compounded with issues in accessibility which continue to impact low-income individuals and will not be resolved with a decrease in the price of Taxol. The results of our analysis indicate that for the biosynthesis of Taxol as well as similar price decreases in other pharmaceuticals, scientists and policymakers alike will have to address more systemic issues in the healthcare system in order for price decreases to truly impact a broad range of individuals.
